2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11A.26 Evaluating Efficacy and Safety of Nivolumab in Pretreated NSCLC Patients: Insights from Real-World Data

EP.11A.26 Evaluating Efficacy and Safety of Nivolumab in Pretreated NSCLC Patients: Insights from Real-World Data

Pdf Summary

This study by Marko Jakopovic and colleagues at University Hospital Centre Zagreb evaluates the efficacy and safety of nivolumab, an anti-PD-1 agent, in treating patients with pretreated metastatic non-small cell lung cancer (NSCLC). Since immunotherapies like nivolumab were approved in 2014 for second-line NSCLC treatment, they have shown improved efficacy compared to traditional options like docetaxel. This non-interventional, retrospective cohort study focuses on real-world data from 105 patients who received nivolumab after progression on standard chemotherapy between March and October 2017.<br /><br />The primary goal was to assess nivolumab's safety and effectiveness in this context. Patients were monitored until November 2023 for disease progression and overall survival (OS), with a median follow-up of approximately 79.9 months for progression-free survival (PFS) and 82.4 months for OS. Despite prior treatments, the study noted a median overall survival of 15.9 months and a median PFS of 7.07 months.<br /><br />Side effects were observed in 22 patients (20.9%), with 16 discontinuing treatment. Pneumonitis was the most common side effect, followed by endocrine disorders and rash. Interestingly, patients who experienced side effects showed a significantly longer median PFS of 13.2 months compared to 6.1 months for those without side effects, suggesting a correlation between side effects and improved survival outcomes.<br /><br />Conclusively, this study highlights the real-world benefits of nivolumab for heavily pretreated NSCLC patients, demonstrating a survival advantage consistent with extensive clinical trial data. The results underscore the importance of monitoring side effects, which may predict better treatment responses.

Asset Subtitle

Marko Jakopovic

Meta Tag

Speaker Marko Jakopovic

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

nivolumab

NSCLC

immunotherapy

metastatic lung cancer

real-world data

survival outcomes

side effects

pneumonitis

progression-free survival

overall survival